Author/Authors :
Yazdani, Shahla Gynecology Department - Fatemeh-Zahra Infertility and Reproductive Health Research Center - Babol University of Medical Sciences, Babol, Iran , Rouholahnejad, Rahele Student Research Committee - Babol University of Medical Sciences, Babol, Iran , Asnafi, Nesa Obstetrics & Gynecology Department - Fatemeh-Zahra Infertility and Reproductive Health Research Center - Babol University of Medical Sciences, Babol, Iran , Sharbatdaran, Majid Pathology Department - Babol University of Medical Sciences, Babol, Iran , Zakershob, Marziihe Babol University of Medical Sciences - Ayatoollah Rohani Hospital Babol, Iran , Bouzari, Zinatossadat Obstetrics & Gynecology Department - Member of Cellular & Molecular Biology Research Center - Babol University of Medical sciences, Babol Iran
Abstract :
Background: Abnormal levels of the markers AFP, hCG, and uE3 could be useful in predicting
adverse pregnancy outcomes. This study was designed to determine the correlation between second
trimester maternal serum markers and adverse pregnancy outcome (APO).
Methods: In this historical cohort study, we randomly followed 231 obstetric patients with quadruple
screening test in 14-18 weeks of gestation from March 2012 to March 2013 in a medical laboratory
in Babol, Iran. We measured maternal serum levels of alphafetoprotein (AFP), human chorionic
gonadotropin (hCG), unconjugated estriol (uE3), and inhibin-A. The risk of adverse pregnancy outcomes
(APOs) were then compared between patients with negative and positive test results. We used
Chi-square and Fisher-exact tests for qualitative variables and t-test for quantitative variables. Demographic
differences between the two groups were minimized by applying logistic regression.
Results: The risk of having an APO such as pre-eclampsia (p=0.008), fetal growth restriction
(p=0.028) and premature rupture of membrane (p=0.040) increased significantly in patients with
abnormal markers.
Conclusion: Abnormal results of quadruple screening test could be associated with APO in women
with normal appearing fetus.